Monoclonal Antibodies Against the Human Respiratory Syncytial Virus Obtained by Immunization with Epitope Peptides and CpG-DNA-liposome Complex

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Volumn 34, Issue 2, 2015, Pages 101-109

  Park, Byoung Kwon ^a   Choi, Song Hee ^a   Kim, Young Eun ^b   Park, Sangkyu ^b   Lee, Younghee ^b   Lee, Keun Wook ^a   Kwon, Hyung Joo ^a  

^a Hallym University   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANAZOLENE SODIUM; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; EPITOPE; ETHANOLAMINE DERIVATIVE; IMMUNOGLOBULIN G; LIPOPLEX; LIPOSOME; MONOCLONAL ANTIBODY; PHOSPHATIDYL BETA OLEOYL GAMMA PALMITOYL ETHANOLAMINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; BACTERIAL DNA; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; PEPTIDE FRAGMENT; PROTEIN BINDING; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISSOCIATION CONSTANT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYBRIDOMA; IMMUNIZATION; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IMMUNOTHERAPY; INFLUENZA VIRUS A H5N1; MOUSE; MYELOMA CELL; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SPLEEN CELL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; CHLOROCEBUS AETHIOPS; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MYCOBACTERIUM BOVIS; TUMOR CELL LINE; VERO CELL LINE;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, VIRAL; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; DNA, BACTERIAL; EPITOPES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; HYBRIDOMAS; IMMUNIZATION; LIPOSOMES; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDE FRAGMENTS; PROTEIN BINDING; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VERO CELLS;

EID: 84928482305     PISSN: None     EISSN: 21679436     Source Type: Journal    
DOI: 10.1089/mab.2014.0089     Document Type: Article

References (39)

1. Blount RE Jr, Morris JA, and Savage RE: Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 1956;92:544-549.
2. Englund JA, Sullivan CJ, Jordan MC, Dehner LP, Vercellotti GM, and Balfour HH Jr: Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988;109:203-208.
3. Harris J, and Werling D: Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell Microbiol 2003;5:671-680.
4. Kong X, San Juan H, Kumar M, Behera AK, Mohapatra A, Hellermann GR, Mane S, Lockey RF, and Mohapatra SS: Respiratory syncytial virus infection activates STAT signaling in human epithelial cells. Biochem Biophys Res Commun 2003;306:616-622.
5. Breary SP, and Smyth RL: Pathogenesis of RSV in children. In: Perspectives in Medical Virology, vol 14. Cane PA (Ed.). Elsevier Publishers, Amsterdam, 2006, pp. 141-162.
6. Hendricks DA, Baradaran K, McIntosh K, and Patterson JL: Appearance of a soluble form of the G protein of respiratory syncytial virus in fluids of infected cells. J Gen Virol 1987;68:1705-1714.
7. Hendricks DA, McIntosh K, and Patterson JL: Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J Virol 1988;62:2228-2233.
8. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, and Parrott RH: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89:422-434.
9. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC 3rd, and Murphy BR: Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994;68:5321-5325.
10. Boelen A, Andeweg A, Kwakkel J, Lokhorst W, Bestebroer T, Dormans J, and Kimman T: Both immunization with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice. Vaccine 2000;19:982-991.
11. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, and Polack FP: Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009;15:34-41.
12. Hancock GE, Speelman DJ, Frenchick PJ, Mineo-Kuhn MM, Baggs RB, and Hahn DJ: Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine 1995;13:391-400.
13. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, and Cosco C: Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 1996;70:7783-7791.
14. Haynes LM, Caidi H, Radu GU, Miao C, Harcourt JL, Tripp RA, and Anderson LJ: Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis 2009;200:439-447.
15. Melero JA: Molecular biology of human respiratory syncytial virus. In: Perspectives in Medical Virology, vol 14. Cane PA (Ed.). Elsevier Publishers, Amsterdam, 2006, pp. 1-42.
16. Malley R, DeVincenzo J, Ramilo O, Dennehy PH, Meissner HC, Gruber WC, Sanchez PJ, Jafri H, Balsley J, Carlin D, Buckingham S, Vernacchio L, and Ambrosino DM: Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998;178:1555-1561.
17. The Impact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-537.
18. Yu JR, Kim S, Lee JB, and Chang J: Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J Virol 2008;82:2350-2357.
19. Kim S, Joo DH, Lee JB, Shim BS, Cheon IS, Jang JE, Song HH, Kim KH, Song MK, and Chang J: Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant. PLoS One 2012;7:e32226.
20. Kim D, Kwon S, Ahn CS, Lee Y, Choi SY, Park J, Kwon HY, and Kwon HJ: Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA. BMB Rep 2011;44:758-763.
21. Kim D, Kwon S, Rhee JW, Kim KD, Kim YE, Park CS, Choi MJ, Suh JG, Kim DS, Lee Y, and Kwon HJ: Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol 2011;18;12-29.
22. Park BK, Kim D, Wu G, Choi SH, Kim DS, Lee Y, and Kwon HJ: Effect of epitope-CpG-DNA-liposome complex without carriers on vaccination of respiratory syncytial virus infection. J Korean Soc Appl Biol Chem 2014;57:667-676.
23. Jang JE, Lee JB, Kim KH, Park SM, Shim BS, Cheon IS, Song MK, and Chang J: Evaluation of protective efficacy of respiratory syncytial virus vaccine against A and B subgroup human isolates in Korea. PLoS One 2011;6:e23797.
24. Kyte J, and Doolittle RF: A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982;157:105-132.
25. Emini EA, Hughes JV, Perlow DS, and Boger J: Induction of hepatitis A virus-neutralizing antibody by a virusspecific synthetic peptide. J Virol 1985;55:836-839.
26. Eisenberg D, Weiss RM, and Terwilliger TC: The hydrophobic moment detects periodicity in protein hydrophobicity. Proc Natl Acad Sci USA 1984;81:140-144.
27. Jameson BA, and Wolf H: The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci 1988;4:181-186.
28. Yokoyama WM, Christensen M, Santos GD, and Miller D: Production of monoclonal antibodies. Curr Protoc Immunol 2006;Ch 2:Unit 2.5.
29. Krieg AM: The role of CpG motifs in innate immunity. Curr Opin Immunol 2000;12:35-43.
30. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-145.
31. Klinman DM, Currie D, Gursel I, and Verthelyi D: Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004;199:201-216.
32. Kim D, Kwon S, Ahn CS, Lee Y, Choi SY, Park J, Kwon HY, and Kwon HJ: Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA. BMB Rep 2011;44:758-763.
33. Kim D, Lee JY, Song DG, Kwon S, Lee Y, Pan CH, and Kwon HJ: A monoclonal antibody against the human SUMO-1 protein obtained by immunization with recombinant protein and CpG-DNA-liposome complex. Monoclon Antib Immunodiagn Immunother 2013;32:354-361.
34. Kim D, Kwon HJ, and Lee Y: Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA. BMB Rep 2011;44:607-612.
35. Rhee JW, Kim D, Park BK, Kwon S, Cho S, Lee I, Park MS, Seo JN, Kim YS, Choi HS, Lee Y, and Kwon HJ: Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice. PLoS One 2012;7:e48750.
36. Kwon S, Kim D, Park BK, Cho S, Kim KD, Kim YE, Park CS, Ahn HJ, Seo JN, Choi KC, Kim DS, Lee Y, and Kwon HJ: Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One 2012;7:e33121.
37. Johnson PR, and Collins PL: The A and B subgroups of human respiratory syncytial virus: comparison of intergenic and gene-overlap sequences. J Gen Virol 1988;69:2901-2906.
38. González-Reyes L, Ruiz-Argüello MB, Garciá-Barreno B, Calder L, López JA, Albar JP, Skehel JJ, Wiley DC, and Melero JA: Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci USA 2001;98:9859-9864.
39. Chambers P, Pringle CR, and Easton AJ: Sequence analysis of the gene encoding the fusion glycoprotein of pneumonia virus of mice suggests possible conserved secondary structure elements in paramyxovirus fusion glycoproteins. J Gen Virol 1992;73:1717-1724.